Overexpression of peroxisome proliferator activator receptor g (PPARg) has been implicated in many types of cancer including cervical cancer. Radiation therapy remains the main nonsurgical modality for the treatment of cervical cancer. The present study reports the impact of pharmacological inhibition of PPARg in enhancing the radiosensitization of cervical cancer cells in vitro. Three cervical cancer cell lines (HeLa, SiHa, and Me180) were treated with a PPARg inhibitor, T0070907, and/or radiation. The changes in protein, cell cycle, DNA content, apoptosis, and cell survival were analyzed. The PPARg is differentially expressed in cervical cancer cells with maximum expression in ME180 cells. T0070907 has significantly decreased the tubulin levels in a time-dependent manner in ME180 cells. The decrease in the tubulin levels after T0070907 in ME180 and SiHa cells was associated with significant increase in the cells at the G2/M phase. The changes in the tubulin and G2/M phase were not evident in HeLa cells. T0070907 reduced the protein levels of PPARg; however, PPARg silencing had no effect on the a-tubulin level in ME180 cells suggesting the PPARg-dependent andindependent actions of T0070907. To ascertain the impact of synergistic effect of T0070907 and radiation, HeLa and ME180 cells were pretreated with T0070907 and subjected to radiation (4 Gy). Annexin V-fluorescein isothiocyanate analysis revealed increased apoptosis in cells treated with radiation and T0070907 when compared to control and individual treatment. In addition, T0070907 pretreatment enhanced radiation-induced tetraploidization reinforcing the additive effect of T0070907. Confocal analysis of tubulin confirmed the onset of mitotic catastrophe in cells treated with T0070907 and radiation. These results strongly suggest the radiosensitizing effects of T0070907 through G2/M arrest and mitotic catastrophe.
Introduction
Despite improvements in screening, cervical cancer remains the third most common cancer and fourth leading cause of cancer death in the world. 1 Epidemiological and laboratorybased studies have identified infection with human papillomavirus (HPV) as the major cause in cervical cancer development. 2 Radiation therapy remains the main nonsurgical modality for the treatment of cervical cancer. Several observations suggest that inhibition of peroxisome proliferator activator receptor g (PPARg) function may be beneficial in treating neoplasms. 3, 4 Although PPARg is overexpressed in many cancer cell types including cervical cancer, 5 loss of function mutations are rare, 6 which suggests that PPARg is a tumor survival factor. Evidence that PPARg function can contribute to carcinogenesis or cancer cell survival includes reports of a murine colon cancer model in which PPARg activation leads to increased tumor formation. 7, 8 A significant correlation between high levels of PPARg expression in pancreatic cancer cells and shorter overall survival time has been reported. 9 In addition, PPARg inhibitors decrease migration and invasion of HT-29 cells and reduces both metastasis number and size in a murine xenograft model. 10 Collectively, these studies highlight the significance of endogenous inhibition of PPARg actions in the treatment of several cancer cell types. Studies reporting the role of PPARg inhibition in augmenting the actions of radiation in cancer cell are very limited and needs to be investigated. T0070907 (PubChem SID: 53790303) was identified as a potent and selective antagonist which shows a more than 800-fold preference for PPARg over PPARa and PPARd. 11 The suppression of PPARg activity by T0070907 has been demonstrated in cell-based reporter gene and functional assays. [10] [11] [12] Moreover, antitumor activity was observed when cancer cells were treated with T0070907. [13] [14] [15] It has also been shown that inhibition of PPARg by T0070907 suppressed pancreatic cell motility in vitro and invasion in vivo. 12 Furthermore, T0070907 reduced tubulin protein levels resulting in cell cycle arrest, apoptosis and reduced metastasis of colorectal carcinoma cells. 10 Cells in M and G2 phases are most radiosensitive 16 than other phases and T0070907 treatment has been shown to induce G2/M. Hence, we have speculated that T0070907 can be exploited as a radiosensitizer. To date, there is no report available on the radiosensitizing role of T0070907.
In this study, the mechanisms underlying the synergistic effect of radiation and PPARg antagonist treatment in cervical cancer cells were evaluated. The present study examined the changes in the tubulin, DNA content, and apoptosis to delineate the beneficial effects of radiation and T0070907. The data generated in the present study suggest enhanced apoptosis, G2/M arrest, and mitotic catastrophe in ME180 cervical cancer cells by T0070907 upon irradiation. The data also highlight the significance of pharmacological inhibition of endogenous activity of PPARg by T0070907. T0070907 may provide a novel and effective therapeutic approach for enhancing the radio sensitization therapy in cervical cancer.
Materials and Methods

Cell Culture and Treatments
HeLa (HPV 18), SiHa (HPV 16), and ME-180 (HPV 68) cells with wild-type p53 were obtained from Korea cell line bank, Seoul, Korea, and were cultured in Dulbecco Modified Eagle Medium or Roswell Park Memorial Institute medium medium (WelGENE; Daegu, Korea) with 100 units/mL penicillin, 100 mg/mL streptomycin, and 10% fetal bovine serum (FBS) and incubated at 37 C in a humidified atmosphere of 95% air and 5% CO 2 . T0070907 (Cayman, Michigan) was dissolved in dimethyl sulfoxide (DMSO) vehicle. Cells were treated with 50 mmol/L at indicated time points with 0.1% FBS media and then cells were irradiated with a 6 MV linear accelerator (Siemens Mevatron M6700; Concord, CA), at a dose rate of 3 Gy/min and incubated at 37 C at indicated time points.
Cell Cycle Analysis Using Bromodeoxyuridine Fluorescein Isothiocyanate Assay
For cell cycle analysis, cells were pretreated with or without T0070907 at indicated time points and were pulse labeled with 10 mmol/L bromodeoxyuridine (BrdU) for 30 minutes and harvested using trypsinization. Cells were then fixed and stained using fluorescein isothiocyanate (FITC)-conjugated anti-BrdU and 7-aminoactinomycin D (7-AAD) following manufacturer's instruction (BD BrdU Flow Kits #559619, BD Biosciences, CA). Finally, thecells were analyzed by BD FACS Calibur cytometry (BD Biosciences, California).
Western Blot Analysis
Cells pretreated with or without T0070907 were left untreated or irradiated and incubated at indicated time points at 37 C, 5% CO 2 . The cells were then washed with ice-cold phosphatebuffered saline (PBS) and lysed using cell lysis buffer (Cell Signaling: Beverly, MA), containing protease and phosphatase inhibitors (Roche, Mannheim, Germany). Cellular debris were cleared by centrifugation at 12000 rpm for 15 minutes at 4 C. The protein concentration in each sample was determined using BioRad reagent (BioRad; Hercules, CA). An equal amount of protein was subjected to sodium dodecyl sulfate-polyacyrlamide gel electrophoresis and transferred onto a polyvinylidene difluoride membrane (Millipore; Bedford, MA). The membrane was then blocked using blocking buffer and washed in 0.2% trisbuffered saline-containing Tween 20 (TBST) for 5 minutes. The membrane was incubated overnight with appropriate primary antibodies. Subsequently, the membranes were washed in 0.2% TBST for 10 minutes followed by incubation with appropriate secondary antibody for 50 minutes. The proteins were visualized using enhanced chemiluminescence (West-Zol plus, iNtRON Biotechnology; Seongnam, Korea).
Clonogenic Assay
Cells in growing phase were treated with either vehicle (DMSO) or T0070907 50 mmol/L at indicated time points and then irradiated. Varying number (100-2000) of cells for optimal colony counting was seeded in 60-mm dishes according to the presence or absence of T0070907 and radiation. After 14 days, the cells were stained with 0.1% crystal violet solution and colonies which are composed of at least 50 cells were counted.
Assessment of Apoptosis
Apoptosis was measured by flow cytometry using FITC Annexin V Apoptosis Detection Kit (BD Pharmingen). Cells were collected at indicated time points following radiation. Then, the cells were resuspended in binding buffer and 5 mL of FITC Annexin V and propidium iodide were added. The cells were then incubated for 15 minutes at room temperature (25 C) in the dark and then 400 mL of binding buffer was added to each sample and analyzed using flow cytometry (BD Biosciences) within 1 hour.
Confocal Microscopy
ME-180 cells were grown on coverslips placed in 35-mm dishes and pretreated with or without T0070907 were irradiated (4 Gy) as described earlier and incubated at indicated time points. After incubation time, cells were fixed with 4% paraformaldehyde in PBS and then permeabilized with 0.1% Triton X-100 and blocked with 10% FBS for 30 minutes followed by incubation with anti-a-tubulin antibody (1:100, Santa Cruz, CA) in 2% FBS/PBS overnight at 4 C. Cells were further incubated with Alexa-488 conjugated secondary antibody for 1 hour. Nuclei were stained with 4',6-diamidino-2phenylindole (DAPI; 1 mg/mL, Sigma, St Louis, MO). Coverslips were mounted onto slides and images were captured and analyzed using confocal microscope (Leica DM-IRB; Mannheim, Germany).
Statistical Analysis
The significance of the observation was estimated by Student's t test, using data from at least 3 independent replicates. The 
Results
Peroxisome Proliferator Activator Receptor g Is Differentially Expressed in Cervical Cancer Cells
Peroxisome proliferator activator receptor g is overexpressed in many cancer cell types including cervical cancer 5 suggesting that PPARg is a tumor survival factor. Therefore, an attempt has been made to evaluate the expression of PPARg in 3 different cervical cancer cells viz HeLa, ME180, and SiHa ( Figure 1A ). The expression of PPARg was maximal in ME180 cells followed by SiHa cells. The expression of PPARg is feeble in HeLa cells. These observations suggest that PPARg may function as a survival factor in ME180 cells.
T0070907 Reduces Tubulin Protein Level in ME180 Cells
Functioning of microtubule network requires the maintenance of critical threshold of tubulin proteins. T0070907 treatment has reduced the levels of aand b-tubulin protein in a timedependent manner in ME180 and SiHa cells; however, such a reduction was not observed in HeLa cells suggesting the cell type-specific effect of T0070907. The Western blot data on the reduction in tubulin proteins in ME180 and SiHa cells by T0070907 were corroborated with confocal microscopy analysis showing reduced a-tubulin levels. The changes in the levels of tubulin were not evidenced in HeLa cells ( Figure 1B and C).
T0070907 Alters Cell Cycle Distribution
Cell cycle analysis was performed using flow cytometry to examine whether the cell cycle distribution profiles and DNA content were affected by T0070907 as a manifestation of its antiproliferative action. As illustrated in Figure 2 , T0070907 treatment induced a significant G2/M phase arrest in ME180 and SiHa cells in a time-dependent manner (12, 24, and 48 hours). There was no difference observed at G2/M phase after T0070907 treatment in HeLa cells after 12, 24, and 48 hours. T0070907 treatment decreased the synthesis of DNA in SiHa and ME180 cervical cancer cells. (Figure 2 ).
T0070907 Prevents the Radiation-Induced Alterations in the Cell Cycle Regulatory Proteins
Since T0070907 has promoted the apoptosis and induced cell cycle arrest in control and irradiated cancer cells, we wanted to delineate the role of T0070907 in the protein levels of cell division cycle (Cdc) 2, phospho-Cdc (p-Cdc) 2, Cdc25c, pCdc25c, and cyclin B1 ( Figure 3A and B) . Radiation treatment has resulted in a time-dependent increase in the expression of this protein, whereas T0070907 pretreatment has prevented the radiation-induced increase in these proteins in ME180 and HeLa cells. The induction of cyclin B1 and regulatory proteins suggests one of the mechanisms by which cells acquire radioresistance and the preventive actions of T0070907 suggest its radiosensitizing ability.
T0070907 Reduces Colony Formation in Irradiated Cells
The ability of cells to proliferate and form colonies has been recognized generally as the single most reliable in vitro marker of premalignant or malignant transformation. 17 Hence, an attempt has been made to delineate the synergistic effect of T0070907 (50 mmol/L, 24 hours) and radiation on colony formation. Significant reductions in the number of colonies were evidenced in cells treated with T0070907 after different dose of radiation in ME180 cells when compared with radiation alone. Such reduction in the ability to form colony after T0070907 was not evidenced in HeLa cells after different doses of radiation ( Figure 4A and B) . 
T0070907 Accelerates the Radiation-Induced Apoptosis
Radiation has been shown to induce apoptosis and decrease the survival of cancer cells. Hence, the impact of radiation on the induction of apoptosis was evaluated in ME180 ( Figure 5A and B) and HeLa cells ( Figure 5C and D) treated with or without T0070907. Radiation failed to significantly increase the apoptosis in both cell lines tested; however, T0070907 promoted apoptosis in ME180 cells and the apoptosis was maximum in both HeLa and ME180 cells treated with T0070907 and radiation. T0070907 has promoted the induction of protein levels of p53 by radiation suggesting the radiosensitizing effect of T0070907 in ME180 cervical cancer cells is p53 dependent (Figure 5E ).
T0070907 and Radiation-Induced Mitotic Catastrophe
Mitotic catastrophe is another major modality of cell death in irradiated cells. Since T0070907 treatment has reduced the levels of tubulins significantly in ME180 cells and mitotic catastrophe is reported in cells with disrupted microtubules, we wanted to address the impact of T0070907 and radiation on the onset of mitotic catastrophe. To determine mitotic catastrophe, cell cycle analysis was measured following 4 Gy radiation in cells treated with or without T0070907. Increase in tetraploidization is evidenced after 24 and 48 hours in ME180 cells after radiation. Cells with 8 N DNA content were evidenced in ME180 cells treated with radiation and T0070907. There was no significant polyploidy cells increase in HeLa cells ( Figure 6A and B) . To further validate the findings of flow cytometric analysis, immunofluorescence was performed in ME180 cells treated with or without T0070907 alone or in combination with radiation. After treatment, cells were stained with anti-a-tubulin and DAPI, and cells with multinucleation or micronucleation were counted as mitotic catastrophe cells. T0070907 and radiation treatment alone induced a little increase in cells with mitotic catastrophe at 24 and 48 hours postirradiation ( Figure 6C and  D) . Interestingly, the combined treatment significantly elevated mitotic catastrophe cells at both time points.
Discussion
DNA-damaging agents in the form of ionizing radiation and chemotherapeutic drugs are the main components of most current cancer treatment regimens. 18 Antimitotic drugs that disrupt the function of mitotic spindle by altering polymerization dynamics of microtubules have been extensively used for cancer therapy. The present study evidenced a timedependent significant reduction in the protein levels of aand b-tubulin, suggesting the microtubule targeting actions of T0070907 as tubulins are the functional units of microtubules. The decreases in the tubulins observed in the present study are in agreement with earlier studies wherein T0070907 has accelerated the proteasomal degradation of tubulins. The decrease in the tubulins after T0070907 treatment was associated with cell cycle arrest at G2/M phase. Interestingly, the decrease in the level of tubulins and cell cycle arrest was evident only in ME180 and SiHa cells not in the other cell types studied. Therefore, it can be stated the actions of T0070907 are cell type specific. However, reduction in the synthetic phase is evident in both SiHa and ME180 cells. Differential expression pattern of PPARg might be one of the potential mechanisms responsible for the cell type-specific effect of T0070907 on G2/M transition. T0070907 treatment has decreased the protein levels of PPARg in a time-dependent manner suggesting the actions of T0070907 in ME180 involve PPARg. However, PPARg silencing did not result in the tubulin reduction in ME180 cells suggesting the possible involvement of other factors in the radiosensitizing effect of T0070907 in ME180 cells (Supplementary figure) .
There is no appreciable cell death observed in ME180 cells following irradiation after 24 hours. Radiation treatment has upregulated the levels of total and phosphorylated Cdc25c and Cdc2 proteins in a time-dependent manner along with elevated cyclin B1 levels. Cyclin B1 forms with Cdc2 (cyclin-dependent kinase [Cdk] 1), a complex called mitosis promoting factor that is crucial for G2/M transition. 19 Insufficient levels of cyclin B-Cdk1 complexes are related to cell cycle arrest at G2. 20 Cyclin B1 is also considered as a potential prognostic marker in different cancers. 21, 22 T0070907 pretreatment has reduced the radiation-induced increase in the levels of cyclin B1 and the levels of total and phosphorylated Cdc25c and Cdc2. This can be attributed for augmented apoptosis and cell cycle arrest induced in cells treated with T0070907 and radiation.
An increase in the tetraploidization and multinucleation was noted in irradiated cells pretreated with T0070907 when compared with control and irradiation-treated cells suggesting the induction of chromosomal aberration. Often, irradiated cells adapt to the mitotic checkpoint and consequently do not die by apoptosis in metaphase. These cells exit the arrest but fail cytokinesis and enter the next G1 phase with a tetraploid DNA content. 23, 24 As a result, giant polyploid cells will be generated with aberrant nuclear morphology, [25] [26] [27] multiple nuclei, 25, 28 and/or several micronuclei. 29 These cells can survive for days but in the end, they die by delayed necrosis, delayed apoptosis, or induced senescence. 30 Apoptosis in G1 occurs shortly after tetraploidization and is largely dependent on p53 activation of the Bax-dependent mitochondrial pathway. 30 These cells can continue through several cycles of cell division, acquiring an increasing amount of chromosomal aberration, finally causing death via delayed apoptosis or delayed necrosis. Collectively, these observations point the significance of tetraploidization after irradiation in the execution of cell death.
Pretreatment with T0070907 has promoted radiation-induced apoptosis and mitotic catastrophe in ME180 cells suggesting the beneficial effects of synergistic treatment with T0070907 and radiation. Apoptosis is characterized morphologically by cytoplasmic shrinkage, chromatin condensation, and nuclear fragmentation with chromatinolysis, 31 and biochemically by caspase activation and permeabilization of the outer mitochondrial membrane. [32] [33] [34] Mitotic catastrophe is a special case of apoptosis and occurs during mitosis with a combination of deficient cell cycle checkpoints and cellular damage. 35 DNA damage activates checkpoints to delay cell cycle progression. T0070907 induced increase in the protein levels of p53 after irradiation suggesting that the apoptotic effect of T0070907 is p53 dependent. p53 regulates G1/S transition (G1-checkpoint), while checkpoint kinase 1 (CHK1) prevents the entry of DNAdamaged cells into M-phase (G2-check point). In the case of chemoresistance, DNA damage induced by chemotherapeutic agents fails to arrest the cancer cells in the G1 phase and to promote apoptosis owing mainly to the deficient p53 signaling.
However, DNA damage can activate the CHK1 pathway, induce S-and G2-checkpoints arrest, 36, 37 and facilitate DNA repair before entry into mitosis (M phase). It is therefore conceivable that agents capable of inducing conventional apoptosis (through DNA damage and p53 activation) and promoting mitotic catastrophe (via CHK1 inactivation and abrogation of G/M arrest) may offer potentially new therapeutic advantages. Previous investigations have shown that both PPARg agonists and antagonists act as effective anticancer agents. 38, 39 The role of PPARg agonists as anticancer agents has been well characterized in the treatment of colon, gastric, and lung cancer, 40, 41 whereas, PPARg antagonists have been shown to induce potent antiproliferative effects in many hematopoietic and epithelial cancer cell lines. 38, 41 Results in the present study confirm and extend these previous findings. Dose-response studies showed that treatment with either PPARg antagonist significantly inhibited the growth of human MCF-7 and MDA-MB-231 breast cancer cells in culture. Antiproliferative effects of PPARg antagonist were found to be more pronounced in MDAMB-231 than that in MCF-7 breast cancer cells, and these results are similar to those reported previously. 38, 42 Also,in the present study, , the antiproliferative actions of T0070907 are more evident in ME180 cells than in other cell types studied. These findings suggest that antiproliferative action of PPARg is cell type dependent and offers support to the differential effects of T0070907 in cervical cancer cells. More importantly, T0070907 has radiosensitized the ME180 and greatly reduced its ability to form colonies. Although increased apoptosis was noted in HeLa cells treated with radiation and T0070907, no significant reduction is observed in the ability of HeLa cells treated with radiation and T0070907 when compared with control cells to form colony suggesting that the induction of apoptosis and suppression of clonogenicity are independent processes. These observations are in line with an earlier study wherein cells that readily underwent apoptosis did not necessarily show a correlated loss of clonogenicity; for example, Me45 (human melanoma) cells showed the highest sensitivity to irradiation in clonogenic assays but much lower levels of apoptotic cells than R1 (rat rhabdomyosarcoma), or HL-60 cells (promyelocytic leukemia). 43 
Conclusion
The data generated in the present study report the alterations in the levels of tubulin, enhanced cell cycle arrest, tetraploidization, multinucleation, apoptosis, and reduced ability to form clones following T0070907 pretreatment and irradiation in cervical cancer ME180 cells. Taken together, these observations strongly support the induction of radiosensitization by T0070907 and offer new perspectives in the radiotherapy for cervical cancer. Emerging studies also point out the therapeutic efficacy of PPARg agonist in the treatment of cancer and in this context the present study warrants extensive investigation before advocating PPARg agonist therapy.
